文 献1）Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov disord 2008; 23 Suppl 3: S497-508.6）Solinas M, Belujon P, Fernagut PO, Jaber M, Thiriet N. Dopamine and addiction: what have we learned from 40 years of research. J Neural Transm 2019; 126: 481-516.8）London ED. Human brain imaging links dopaminergic systems to impulsivity. Curr Top Behav Neurosci 2020; 47: 53-71.9）Lee B, London ED, Poldrack RA, Farahi J, Nacca A, Monterosso JR, et al. Striatal dopamine D2/D3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neuroscience 2009; 29: 14734-40.10）Ghahremani DG, Lee B, Robertson CL, Tabibnia G, Morgan AT, De Shetler N, et al. Striatal dopamine D2/D3 receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans. J Neurosci 2012; 32: 7316-24.11）Moeller SJ, Okita K, Robertson CL, Ballard ME, Konova AB, Goldstein RZ, et al. Low striatal dopamine D2-type receptor availability is linked to simulated drug choice in methamphetamine users. Neuropsychopharmacology 2018; 43: 751-60.2）Tripp G, Wickens JR. Neurobiology of ADHD. Neuropharmacology 2009; 57: 579-89.3）Kollins SH, Adcock RA. ADHD, altered dopamine neurotransmission, and disrupted reinforcement processes: implications for smoking and nicotine dependence. Prog Neuropsychopharmacol Biol Psychiatry 2014; 52: 70-8.4）Wang GJ, Geliebter A, Volkow ND, Telang FW, Logan J, Jayne MC, et al. Enhanced striatal dopamine release during food stimulation in binge eating disorder. Obesity (Silver Spring) 2011; 19: 1601-8.5）Frank GKW. Neuroimaging and eating disorders. Curr Opin Psychiatry 2019; 32: 478-83.7）Ashok AH, Mizuno Y, Volkow ND, Howes OD. Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. JAMA psychiatry 2017; 74: 511-9.12）Okita K, Morales AM, Dean AC, Johnson MC, Lu V, Farahi J, et al. Striatal dopamine D1-type receptor availability: no difference from control but association with cortical thickness in methamphetamine users. Mol Psychiatry 2018; 23: 1320-7.13）Ferré S, Bonaventura J, Tomasi D, Navarro G, Moreno E, Cortés A, et al. Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer. Neuropharmacology 2016; 104: 154-60.14）Volkow ND, Wang GJ, Logan J, Alexoff D, Fowler JS, Thanos PK, et al. Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain. Transl Psychiatry 2015; 5: e549.15）Kondo T, Mizuno Y. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. Clinl neuropharmacol 2015; 38: 41-6.16）Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 2009; 56 Suppl 1: 3-8.17）Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PR. The dopamine theory of addiction: 40 years of highs and lows. Nat Rev Neurosci 2015; 16: 305-12.18）Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001; 53: 1-24.19）Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004; 9: 557-69.20）Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, et al. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 2002; 277: 18091-7.21）Ribeiro JA, Sebastiao AM. Caffeine and adenosine. J Alzheimers Dis 2010; 20 Suppl 1: S3-15.115
元のページ ../index.html#129